For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they ...

USF’s Memory Disorders Clinic fielding requests from patients and their families hoping that Donanemab can slow progressive ...

The study, published in JAMA, analyzed postmortem brain tissue from 15 individuals with Down syndrome aged 43 to 68 years ...

Lecanemab is the first treatment for Alzheimer's licensed for use in the country that shows some evidence of slowing the ...

The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent ...

Over the past few years, the Food and Drug Administration has approved various new treatments for Alzhimer's disease, but are ...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

Shortly after a U.K. watchdog declined to endorse Biogen's ( NASDAQ: BIIB) Alzheimer's drug Leqembi for use in the country's ...

Lilly's donanemab sails through FDA meeting with 2 unanimous votes in favor Behind Kisunla, Lilly has remternetug in phase 3 development, which targets amyloid plaques in the brain.

Lecanemab is the most intensive, needing infusions every two weeks, while donanemab infusions are required monthly. Dr Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug ...

The Alzheimer's drug Donanemab is expected to face a block for its use within the NHS, according to a report by The Telegraph. This marks the second time such a drug has faced obstacles within the UK ...